Delbanco Disease: A rare disease described by dermatologist E. Delbanco
Delbanco's disease, also known as Delbanco's dermatitis, is a rare dermatological disorder that was first described by German dermatologist E. Delbanco in 1869. This important discovery in medicine allowed us to more deeply understand the mechanisms of development and manifestation of this disease.
Delbanco The disease is characterized by chronic inflammation of the skin, which primarily affects the flexor surfaces of the joints. The joints most commonly affected are the elbows, knees, wrists and ankles. There is a rash of papules and pustules on the skin, accompanied by itching and peeling. In some cases, ulcers and cracks may appear.
The cause of Delbanco Disease is considered to be a disorder of the immune system, leading to an inadequate response of the body to various irritants. Possible factors contributing to the development of the disease include genetic predisposition, stress, allergic reactions and the environment.
The diagnosis of Delbanco's Disease is usually made based on a clinical examination and review of the patient's medical history. Differential diagnosis is made with other dermatological diseases such as eczema, psoriasis and contact dermatitis.
Treatment for Delbanco's Disease is aimed at reducing inflammation, reducing itching, and preventing flare-ups. Your doctor may prescribe topical medications, such as creams or ointments that contain steroids or immunomodulators. In some cases, systemic medications such as anti-inflammatory drugs or immunosuppressants may be required.
In addition to drug treatment, skin hygiene, avoidance of irritants and contact allergens, and stress management are important measures. Regular consultation with a dermatologist will help monitor the condition and prevent flare-ups.
Although Delbanco Disease is a rare disease, understanding its mechanisms and adequate treatment play an important role in ensuring the comfort and quality of life of patients suffering from this condition. Further research into this disease will lead to the development of more effective diagnostic and treatment methods, opening new opportunities to improve patient outcomes and well-being.